Abstract:Huntington's disease (HD) predominantly affects the brain, causing a mixed movement disorder, cognitive decline and behavioural abnormalities. It also causes a peripheral phenotype involving skeletal muscle. Mitochondrial dysfunction has been reported in tissues of HD models, including skeletal muscle, and lymphoblast and fibroblast cultures from patients with HD. Mutant huntingtin protein (mutHTT) expression can impair mitochondrial quality control and accelerate mitochondrial ageing.Here, we obtained fresh human skeletal muscle, a post-mitotic tissue expressing the mutated HTT allele at physiological levels since birth, and primary cell lines from HTT CAG repeat expansion mutation carriers and matched healthy volunteers to examine whether such a mitochondrial phenotype exists in human HD. Using ultra-deep mitochondrial DNA (mtDNA) sequencing, we showed an accumulation of mtDNA mutations affecting oxidative phosphorylation. Tissue proteomics indicated impairments in mtDNA maintenance with increased mitochondrial biogenesis of less efficient oxidative phosphorylation (lower complex I and IV activity). In full-length mutHTT expressing primary human cell lines, fission-inducing mitochondrial stress resulted in normal mitophagy. In contrast, expression of high levels of N-terminal mutHTT fragments promoted mitochondrial fission and resulted in slower, less dynamic mitophagy. Expression of high levels of mutHTT fragments due to somatic nuclear HTT CAG instability can thus affect mitochondrial network dynamics and mitophagy, leading to pathogenic mtDNA mutations.We show that life-long expression of mutant HTT causes a mitochondrial phenotype indicative of mtDNA instability in fresh post-mitotic human skeletal muscle. Thus, genomic instability may not be limited to nuclear DNA, where it results in somatic expansion of the HTT CAG repeat length in particularly vulnerable cells such as striatal neurons. In addition to efforts targeting the causative mutation, promoting mitochondrial health may be a complementary strategy in treating diseases with DNA instability such as HD. Neueder et al. reveal an accumulation of mitochondrial DNA mutations and impairments in mitochondrial quality control in fresh skeletal muscle samples from patients with Huntington's disease. Accelerated mitochondrial ageing may thus be one of the biological signatures of Huntington's disease, including in peripheral tissues.

A Mitochondria-Associated Oxidative Stress Perspective on Huntington’s Disease

The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons

Dysregulation of Mitochondrial Calcium Signaling and Superoxide Flashes Cause Mitochondrial Genomic DNA Damage in Huntington Disease

Mitochondria in Huntington’s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Huntington disease affects mitochondrial network dynamics predisposing to pathogenic mtDNA mutations

Mitochondrial targeted antioxidants as potential therapy for huntington's disease

Metabolic dysregulation in Huntington's disease: Neuronal and glial perspectives

Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission

Huntington's Disease Affects Mitochondrial Network Dynamics Predisposing to Pathogenic Mitochondrial DNA Mutations

Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease

AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.

DNA Damage Repair in Huntington’s Disease and Other Neurodegenerative Diseases

Soluble N-terminal Fragment of Mutant Huntingtin Protein Impairs Mitochondrial Axonal Transport in Cultured Hippocampal Neurons.

Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington's disease

Mitochondria Modulating Therapeutic Approaches in the Management of Huntington's Disease

Progress in studies of gene therapy for Huntington's disease

Therapeutic approaches targeting aging and cellular senescence in Huntington's disease

CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress

Complex Pathogenesis and Therapeutic Strategies

Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications